Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma-Reference-Cited by-同舟云学术

Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Published:2021-03-25 Issue:11 Volume:27 Page:3069-3078
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Peng Zhi,Wei Jia,Wang Feng,Ying Jieer,Deng Yanhong,Gu Kangsheng,Cheng Ying,Yuan Xianglin,Xiao Juxiang,Tai Yanfei,Wang Linna,Zou Jianjun,Zhang Yanqiao,Shen Lin

Funder

Hengrui

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges;MedComm – Oncology;2024-08-08

2. SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report;Frontiers in Immunology;2024-07-12

3. Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis;BMC Cancer;2024-05-17

4. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study;Cancer Immunology, Immunotherapy;2024-05-10

5. Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers;World Journal of Gastrointestinal Oncology;2024-04-15